Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Techniclone advancing development of Tumor Necrosis Therapy into phase II

Sep. 2, 1998

Pivotal clinical trial data for rituximab published

Aug. 28, 1998

Imutec receives patent protection for Virulizin in Canada

Aug. 24, 1998

Available from NIH: immunotoxin for the treatment of ovarian cancer and mesotheliomas

Aug. 20, 1998

BLP25 cancer vaccine enters phase I testing in patients with NSCLC

Aug. 19, 1998

Canadian patent covers Jenner's cancer vaccine

Aug. 13, 1998

Avax to begin pivotal trial with M-Vax in melanoma patients

July 31, 1998

MabThera now available for non-Hodgkin's lymphoma in the U.K.

July 23, 1998

FDA grants second orphan drug designation for ImmTher

July 20, 1998

Medarex begins clinical trials of Bispecific antibody for cancer

July 20, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...